932 results match your criteria accumulation radiotracer

Invasive Fungal Infection in COVID-19-Recovered Patient Detected on 18F-FDG-Labeled Leukocytes PET/CT Scan.

Clin Nucl Med 2021 Jul 26. Epub 2021 Jul 26.

From the Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurgaon, Haryana, India.

Abstract: Occurrence of invasive fungal infections has gained significant attention during recent times in patients with COVID-19. Patients with severe form of COVID-19, such as those treated in the intensive care unit with prolonged steroid use, are particularly vulnerable to secondary bacterial and fungal infections. Disseminated systemic mycosis is a life-threatening condition, especially in immunocompromised patients. Read More

View Article and Full-Text PDF

Extracardiac Accumulation of Technetium-99m-Pyrophosphate in Transthyretin Cardiac Amyloidosis.

JACC Case Rep 2021 Jul 12;3(7):1069-1074. Epub 2021 May 12.

Department of Clinical Pathology, Yawatahama City General Hospital, Ehime, Japan.

This report presents a rare case of acute decompensated heart failure with technetium-99m-pyrophosphate accumulation in extracardiac sites, such as chest and abdominal walls, in addition to intense myocardial uptake of the tracer. Subsequently, an abdominal fat pad fine-needle aspiration biopsy, which provided positive findings for transthyretin amyloidosis, was performed. (). Read More

View Article and Full-Text PDF

A Novel Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor Positive Prostate Cancer.

J Nucl Med 2021 Jul 22. Epub 2021 Jul 22.

British Columbia Cancer Research Center, Canada.

The gastrin-releasing peptide receptor (GRPR) is overexpressed in many solid malignancies, particularly in prostate and breast cancers, among others. We synthesized ProBOMB2, a novel bombesin derivative radiolabeled with Ga and Lu, and evaluated its ability to target GRPR in a preclinical model of human prostate cancer. ProBOMB2 was synthesized on solid phase using Fmoc chemistry. Read More

View Article and Full-Text PDF

18F-FDG PET/CT Imaging of Immune Checkpoint Inhibitor-Related "Retroperitoneal Panniculitis".

Clin Nucl Med 2021 Jul 14. Epub 2021 Jul 14.

From the Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy.

Abstract: A 71-year-old woman was operated on for undifferentiated lung adenocarcinoma. Four months after surgery, she developed bone and adrenal metastases. She underwent palliative radiation therapy of left scapula and right iliac bone. Read More

View Article and Full-Text PDF

Bowel visualization on the lymphoscintigraphy images of a bladder cancer patient due to inadvertent injection of the tracer in the rectal wall.

Asia Ocean J Nucl Med Biol 2021 ;9(2):177-179

Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

The effectiveness of the sentinel lymph node mapping in patients with Urothelial carcinoma of the bladder is under investigation. Single photon emission computed tomography (SPECT/CT) and intraoperative sentinel node biopsy using gamma probe are performed to detect the exact location of the sentinel lymph node to be dissected during the surgery. In this case report, a 73-year old man with high grade urothelial carcinoma was referred to our nuclear medicine department for SPECT/CT, four hours after injection of the radiotracer through cystoscopy. Read More

View Article and Full-Text PDF
January 2021

Selective Imaging of Matrix Metalloproteinase-13 to Detect Extracellular Matrix Remodeling in Atherosclerotic Lesions.

Mol Imaging Biol 2021 Jul 6. Epub 2021 Jul 6.

Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Ontario, K1N 6N5, Canada.

Purpose: Overexpression and activation of matrix metalloproteinase-13 (MMP-13) within atheroma increases susceptibility to plaque rupture, a major cause of severe cardiovascular complications. In comparison to pan-MMP targeting [F]BR-351, we evaluated the potential for [F]FMBP, a selective PET radiotracer for MMP-13, to detect extracellular matrix (ECM) remodeling in vascular plaques possessing markers of inflammation.

Procedures: [F]FMBP and [F]BR-351 were initially assessed in vitro by incubation with en face aortae from 8 month-old atherogenic ApoE mice. Read More

View Article and Full-Text PDF

In Vivo Tracking of the Degradation of Mesoporous Silica through Zr Radio-Labeled Core-Shell Nanoparticles.

Small 2021 Jul 18;17(30):e2101519. Epub 2021 Jun 18.

Soft Matter Nanotechnology Group, CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, San Sebastián, Guipúzcoa, 20014, Spain.

While mesoporous silica nanoparticles (MSNs) are extensively studied as high-potential drug delivery platforms, the successful clinical translation of these nanocarriers strongly depends on their biodistribution, biodegradation, and elimination patterns in vivo. Here, a novel method is reported to follow the in vivo degradation of MSNs by tracking a radioactive label embedded in the silica structure. Core-shell silica nanoparticles (NPs) with a dense core and a mesoporous shell are labeled with low quantities of the positron emitter Zr, either in the dense core or in the mesoporous shell. Read More

View Article and Full-Text PDF

Incidental cardiac uptake in bone scintigraphy: increased importance and association with cardiac amyloidosis.

BJR Case Rep 2021 May 19;7(3):20200161. Epub 2021 Jan 19.

Department of Radiology, Mater Misericordiae University Hospital, Dublin, Ireland.

Extraosseous radiotracer uptake during bone scintigraphy must be carefully assessed and it offers the potential to detect previously undiagnosed disease processes. A range of neoplastic, metabolic, traumatic, ischaemic and inflammatory disorders can cause soft tissue accumulation of bone avid radiopharmaceuticals. Accordingly, cardiac uptake in bone scintigraphy has a broad differential diagnosis and is commonly attributed to ischaemia/infarction related to coronary artery disease. Read More

View Article and Full-Text PDF

Development and evaluation of [F]Flotaza for Aβ plaque imaging in postmortem human Alzheimer's disease brain.

Bioorg Med Chem Lett 2021 Aug 1;46:128164. Epub 2021 Jun 1.

Preclinical Imaging, Department of Radiological Sciences, University of California, Irvine 92697, USA. Electronic address:

Positron emission tomographic (PET) studies of amyloid β (Aβ) accumulation in Alzheimer's disease (AD) have shown clinical utility. The aim of this study was to develop and evaluate the effectiveness of a new fluorine-18 radiotracer [F]Flotaza (2-{2-[2-[F]fluoroethoxy]ethoxy}ethoxy)-4'-N,N-dimethylaminoazobenzene), for Aβ plaque imaging. Nucleophilic [F]fluoride was used in a one-step radiosynthesis for [F]flotaza. Read More

View Article and Full-Text PDF

Ga-FAPI-PET/CT in patients with various gynecological malignancies.

Eur J Nucl Med Mol Imaging 2021 May 29. Epub 2021 May 29.

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.

Purpose: Ga-FAPI (fibroblast activation protein inhibitor) is a novel and highly promising radiotracer for PET/CT imaging. The aim of this retrospective analysis is to explore the potential of FAPI-PET/CT in gynecological malignancies. We assessed biodistribution, tumor uptake, and the influence of pre- or postmenopausal status on tracer accumulation in hormone-sensitive organs. Read More

View Article and Full-Text PDF

Positron emission tomography and magnetic resonance imaging in experimental human malaria to identify organ-specific changes in morphology and glucose metabolism: A prospective cohort study.

PLoS Med 2021 May 26;18(5):e1003567. Epub 2021 May 26.

Clinical Tropical Medicine Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, Australia.

Background: Plasmodium vivax has been proposed to infect and replicate in the human spleen and bone marrow. Compared to Plasmodium falciparum, which is known to undergo microvascular tissue sequestration, little is known about the behavior of P. vivax outside of the circulating compartment. Read More

View Article and Full-Text PDF

Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican.

Adv Ther (Weinh) 2021 Apr 20;4(4). Epub 2021 Jan 20.

Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.

Glioblastoma multiforme (GBM) is the most common and deadliest form of brain tumor and remains amongst the most difficult cancers to treat. Brevican (Bcan), a central nervous system (CNS)-specific extracellular matrix protein, is upregulated in high-grade glioma cells, including GBM. A Bcan isoform lacking most glycosylation, dg-Bcan, is found only in GBM tissues. Read More

View Article and Full-Text PDF

Longitudinal evaluation of a novel BChE PET tracer as an early biomarker in the brain of a mouse model for Alzheimer disease.

Theranostics 2021 26;11(13):6542-6559. Epub 2021 Apr 26.

CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain.

The increase in butyrylcholinesterase (BChE) activity in the brain of Alzheimer disease (AD) patients and animal models of AD position this enzyme as a potential biomarker of the disease. However, the information on the ability of BChE to serve as AD biomarker is contradicting, also due to scarce longitudinal studies of BChE activity abundance. Here, we report C-labeling, stability, biodistribution, and longitudinal study on BChE abundance in the brains of control and 5xFAD (AD model) animals, using a potent BChE selective inhibitor, [C], and positron emission tomography (PET) in combination with computerised tomography (CT). Read More

View Article and Full-Text PDF

Radiolabeling and evaluation of a novel [TcN] complex with deferoxamine dithiocarbamate as a potential agent for bacterial infection imaging.

Bioorg Med Chem Lett 2021 Jul 10;43:128102. Epub 2021 May 10.

Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, PR China. Electronic address:

In order to find a Tc-labeled deferoxamine radiotracer for bacterial infection imaging, deferoxamine dithiocarbamate (DFODTC) was successfully synthesized and it was radiolabeled with [TcN] core to prepare the TcN(DFODTC) complex. TcN(DFODTC) was obtained with high radiochemical purity without further purification. The complex was lipophilic and exhibited good in vitro stability. Read More

View Article and Full-Text PDF

Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers.

Semin Nucl Med 2021 May 5. Epub 2021 May 5.

Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

In the past two decades, PET/CT has become an essential modality in oncology increasingly used in the management of gastrointestinal (GI) cancers. Most PET/CT tracers used in clinical practice show some degree of GI uptake. This uptake is quite variable and knowledge of common patterns of biodistribution of various radiotracers is helpful in clinical practice. Read More

View Article and Full-Text PDF

Synthesis and Evaluation of Novel Norfloxacin Isonitrile Tc Complexes as Potential Bacterial Infection Imaging Agents.

Pharmaceutics 2021 Apr 9;13(4). Epub 2021 Apr 9.

Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.

To develop potential technetium-99m single-photon emission computed tomography (SPECT) imaging agents for bacterial infection imaging, the novel norfloxacin isonitrile derivatives CN4NF and CN5NF were synthesized and radiolabeled with a [Tc][Tc(I)] core to obtain [Tc]Tc-CN4NF and [Tc]Tc-CN5NF. These compounds were produced in high radiolabeling yields and showed hydrophilicity and good stability in vitro. The bacterial binding assay indicated that [Tc]Tc-CN4NF and [Tc]Tc-CN5NF were specific to bacteria. Read More

View Article and Full-Text PDF

Small Molecule, Multimodal, [F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study.

Clin Genitourin Cancer 2021 Mar 19. Epub 2021 Mar 19.

Department of Nuclear Medicine, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey.

Background: A first-in-human study of [F]-BF3-Cy3-ACUPA, a small-molecule contrast agent that can be unimolecularly both positron emitting and fluorescent, is conducted to determine its: its safety, biodistribution, radiation dosimetry, feasibility in tumor detection by preoperative positron emission tomography (PET), as well as its intraoperative fluorescence imaging utility in patients with prostate-specific membrane antigen positive (PSMA) tumors.

Methods: Ten patients aged 66 ± 7 years received a 6.5 ± 3. Read More

View Article and Full-Text PDF

Comparison of FDG and FMISO uptakes and distributions in head and neck squamous cell cancer tumors.

EJNMMI Res 2021 Apr 14;11(1):38. Epub 2021 Apr 14.

Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Purpose: Glycolysis is increased by hypoxia, suggesting a possible correlation between the accumulation of 2-[18F]fluoro-2-deoxy-D-glucose (FDG) in malignant tumors and regional hypoxia defined by 1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole (FMISO) PET. The aim of this study is to investigate the intra-tumoral spatial distribution and quantitative relationship between FDG and FMISO in a cohort of head and neck squamous cell cancer (HNSCC) patients.

Methods: Twenty HNSCC patients with 20 primary tumors and 19 metastatic lymph nodes (LNs) underwent FDG and FMISO PET within 1 week. Read More

View Article and Full-Text PDF

Synthesis and Biological Evaluation of [F]FECNT-d as a Novel PET Agent for Dopamine Transporter Imaging.

Mol Imaging Biol 2021 Apr 13. Epub 2021 Apr 13.

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China.

Purpose: The dopamine transporter (DAT) is a marker of the occurrence and development of Parkinson's disease (PD) and other diseases with nigrostriatal degeneration. 2β-Carbomethoxy-3β-(4-chlorophenyl)-8-(2-[F]-fluoroethyl)nortropane ([F]FECNT), an F-labelled tropane derivative, was reported to be a useful positron-emitting probe for DAT. However, the rapid formation of brain-penetrating radioactive metabolites is an impediment to the proper quantitation of DAT in PET studies with [F]FECNT. Read More

View Article and Full-Text PDF

Neuroimaging Biomarkers of Chronic Traumatic Encephalopathy: Targets for the Academic Memory Disorders Clinic.

Neurotherapeutics 2021 Apr 13. Epub 2021 Apr 13.

Department of Neurology, Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Boston University School of Medicine, 72 E Concord St, Suite B7800, MA, 02118, Boston, USA.

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with exposure to repetitive head impacts, such as those from contact sports. The pathognomonic lesion for CTE is the perivascular accumulation of hyper-phosphorylated tau in neurons and other cell process at the depths of sulci. CTE cannot be diagnosed during life at this time, limiting research on risk factors, mechanisms, epidemiology, and treatment. Read More

View Article and Full-Text PDF

Ga-labeled PET tracers for targeting tumor hypoxia: Role of bifunctional chelators on pharmacokinetics.

Nucl Med Biol 2021 May-Jun;96-97:61-67. Epub 2021 Mar 26.

Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai 400085, India. Electronic address:

Introduction: By virtue of their oxygen dependant accumulation in hypoxic cells, radiolabeled nitroimidazole analogues have been widely used for detecting tumor hypoxia. Present study evaluates two 2-nitroimidazole (2-NIM) based Ga-labeled radiotracers, [Ga]Ga-DOTAGA-2-NIM and [Ga]Ga-NODAGA-2-NIM, for hypoxia targeting applications.

Methods: Bifunctional chelating agents suitable for radiolabeling with Ga, viz. Read More

View Article and Full-Text PDF

Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo.

Sci Rep 2021 Apr 1;11(1):7358. Epub 2021 Apr 1.

Lehrstuhl für Biologische Chemie, Technische Universität München, 85354, Freising (Weihenstephan), Germany.

The lack of a non-invasive test for malignant thyroid nodules makes the diagnosis of thyroid cancer (TC) challenging. Human galectin-3 (hGal3) has emerged as a promising target for medical TC imaging and diagnosis because of its exclusive overexpression in malignant thyroid tissues. We previously developed a human-chimeric αhGal3 Fab fragment derived from the rat monoclonal antibody (mAb) M3/38 with optimized clearance characteristics using PASylation technology. Read More

View Article and Full-Text PDF

False-Positive 68Ga-Fibroblast Activation Protein-Specific Inhibitor Uptake of Benign Lymphoid Tissue in a Patient With Breast Cancer.

Clin Nucl Med 2021 Aug;46(8):e433-e435

From the Department of Nuclear Medicine, University of Health Sciences, Gazi Yaşargil Training and Research Hospital.

Abstract: 68Ga-fibroblast activation protein-specific inhibitor (FAPI)-04 PET/CT was performed in a patient with left lower outer quadrant breast cancer who had 18F-FDG PET/CT imaging. 68Ga-FAPI-04 PET/CT showed higher accumulation of radiotracer in primary tumor and axillary lymph nodes than 18F-FDG PET/CT. In addition, focal increased FAPI uptake was observed in another nodular lesion in the lower inner quadrant in the same breast, which was considered malignant. Read More

View Article and Full-Text PDF

Molecular Imaging of the Efficacy of Aminopeptidase N (APN/CD13) Receptor Inhibitor Treatment on Experimental Tumors Using Ga-NODAGA-c(NGR) Peptide.

Biomed Res Int 2021 10;2021:6642973. Epub 2021 Mar 10.

Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.

Introduction: The aminopeptidase N (APN/CD13) receptor plays an important role in the neoangiogenic process and metastatic tumor cell invasion. Clinical and preclinical studies reported that bestatin and actinonin are cytotoxic to APN/CD13-positive tumors and metastases due to their APN/CD13-specific inhibitor properties. Our previous studies have already shown that Ga-labeled NGR peptides bind specifically to APN/CD13 expressing tumor cells. Read More

View Article and Full-Text PDF

Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules.

J Nucl Med 2021 Mar 19. Epub 2021 Mar 19.

Department of Nuclear Medicine, University Medical Center Freiburg, Freiburg, Germany, Division of Radiopharmaceutical Development, German Cancer Consortium, partner site Freiburg, Freiburg, Germany and German Cancer Research Center, Heidelberg, Germany, Germany.

The evolution of peptidomimetic hybrid molecules for preoperative imaging and guided surgery targeting the prostate-specific membrane antigen (PSMA) significantly progressed over the past years and some approaches are currently evaluated for further clinical translation. However, accumulation in non-malignant tissue such as kidney, bladder, spleen or liver might limit tumor-to-background contrast for precise lesion delineation particularly in a surgical setting. To overcome these limitations a rational linker design aims at the development of a second generation of PSMA-11 based hybrid molecules with enhanced pharmacokinetic profile and improved imaging contrasts. Read More

View Article and Full-Text PDF

Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for Ga-PSMA-11 PET/CT.

J Nucl Med 2021 Mar 12. Epub 2021 Mar 12.

Department of Nuclear Medicine, Medical University Innsbruck, Austria.

The aim of this study was to assess a) the impact of forced diuresis with early furosemide injection on the detection rate of local recurrence (LR) in prostate cancer (PC) patients with biochemical recurrence (BR) referred for Ga-labelled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (Ga-PSMA-11) Positron Emission Tomography/Computed Tomography (PET/CT) and b) whether intravenous administration of furosemide shortly after tracer injection increases renal wash-out of Ga-PSMA-11 before it binds to the PSMA-receptor with possible influence on biodistribution and intensity of tracer uptake in organs with physiologic tracer accumulation. In a retrospective analysis two different groups with 220 prostate cancer patients each, referred for Ga-PSMA-11 PET/CT because of biochemical recurrence after primary therapy, were compared: patients of group one (median prostate specific antigen (PSA): 1.30 ng/ml) receiving no preparation prior to imaging, whereas patients in group two (median PSA: 0. Read More

View Article and Full-Text PDF

Ascorbic acid analogue 6-Deoxy-6-[F] fluoro-L-ascorbic acid as a tracer for identifying human colorectal cancer with SVCT2 overexpression.

Transl Oncol 2021 May 4;14(5):101055. Epub 2021 Mar 4.

Department of Nuclear Medicine & Guangdong Engineering Research Center for Translational Application of Medical Radiopharmaceuticals, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China. Electronic address:

L-ascorbic acid (AA) was reported to have an anti-cancer effect over 40 years. In recent years, several ongoing clinical trials are exploring the safety and efficacy of intravenous high-dose AA for cancer treatment. The lack of appropriate imaging modality limits the identification of potentially suitable patients for AA treatment. Read More

View Article and Full-Text PDF

Bioevaluation of glucose-modified liposomes as a potential drug delivery system for cancer treatment using 177-Lu radiotracking.

J Control Release 2021 04 3;332:301-311. Epub 2021 Mar 3.

Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovića Alasa 12-14, 11000 Belgrade, Belgrade, Serbia.

Liposomes are promising drug's delivery systems due to decreased toxicity of the liposome-encapsulated drug, but wider clinical application requires their more efficient tumor targeting with uptake, controlled drug release and higher shelf life. The unique metabolic characteristics of cancer cells based on higher demand for energy and therefore increased glucose utilization were exploited in the design of glucose modified liposomes (GML) with the aim to provide increased tumor targeting via glucose transporters and increased ability of drug delivery into tumor cells. Tumor accumulating potential of GML and non-glucose liposomes (NGL) were investigated on CT26 and LS174T tumor-bearing mice by simple and reliable radiotracer method using Lu as radioactive marker. Read More

View Article and Full-Text PDF

Data on the and anti-tumor effects of itraconazole, paclitaxel, and the two in combination in HT-29 and YM-1 cancer cell line and HT-29 colon cancer xenograft models.

Data Brief 2021 Apr 11;35:106862. Epub 2021 Feb 11.

Department of Radiopharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran.

Colon cancer is one of the fatal cancers in the world that metastatic potential and resistance to chemotherapy drugs are outstanding causes of cancer-induced mortality [1], [2], [3], [4]. We have investigated and anti-cancer effect of itraconazole and paclitaxel alone and their anti-cancer synergistic effect through MTT assay in YM-1 and HT-29 cell lines and in HT-29 tumor-bearing nude mice. Histopathological experiment was done for further assessment. Read More

View Article and Full-Text PDF

Maximizing the use of batch production of F-FDOPA for imaging of brain tumors to increase availability of hybrid PET/MR imaging in clinical setting.

Neurooncol Pract 2021 Feb 14;8(1):91-97. Epub 2020 Oct 14.

Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.

Background: Amino acid PET imaging of brain tumors has been shown to play an important role in predicting tumor grade, delineation of tumor margins, and differentiating tumor recurrence from the background of postradiation changes, but is not commonly used in clinical practice because of high cost. We propose that PET/MRI imaging of patients grouped to the day of tracer radiosynthesis will significantly decrease the cost of PET imaging, which will improve patient access to PET.

Methods: Seventeen patients with either primary brain tumors or metastatic brain tumors were recruited for imaging on 3T PET/MRI and were scanned on 4 separate days in groups of 3 to 5 patients. Read More

View Article and Full-Text PDF
February 2021